Amneal

Fast-growing global biopharmaceuticals company & leading provider of affordable medicines

Diversified portfolio of 300+ products across Specialty, Biosimilars, Injectables and Retail Generics

Expansive R&D, manufacturing and commercial capabilities at scale with vertical integration

Robust R&D engine generating 20-30 new retail and injectables product launches consistently per year; focused on high-value, complex products

Accelerated revenue and profit growth outlook with higher cash flow generation and continued deleveraging

Diversified portfolio delivering sustainable growth...

Retail Generics
Diversified portfolio of 300+ products across Specialty, Biosimilars, Injectables and Retail Generics

Injectables
Expanding portfolio of 40+ institutional products with new differentiated 505(b)(2) injectables for hospitals

Biosimilars
Drive uptake of 3 commercial biosimilars and expand portfolio with next 5 biosimilars


AvKARE
Expanding presence across channels & dosage forms

Specialty
Branded therapies focused on Neurology and Endocrinology - highlighted by CREXTONT® for PD

International
Market expansion in India, Europe & rest of world

Adjusted EBITDA growth

$ in millions



Financials

$3.15 - 3.25B
+4% to +8% Growth 2026
Net Revenue guidance

$800 - 815M
+16% to 18% Growth 2026
Adj. EBITDA guidance

3.9x
Net leverage as of September 30, 2026

NASDAQ
AMRX

All data as of November 3, 2026.
1. Reflects 2026 guidance as of November 3, 2026. Full year 2026 estimates are based on management's expectations for prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events, among other factors. Adjusted EBITDA is a non-GAAP measure; a discussion of NonGAAP measures is included in the press release issued on November 3, 2026, available at https://investors.amneal.com/news/press-releases/.